INO

INOVIO's Upcoming Presentations: INOVIO will present key data on its lead candidate, INO-3107, at several conferences, including the National HPV Conference and the World Vaccine Congress, highlighting a 72% overall response rate for treating recurrent respiratory papillomatosis caused by HPV.

Focus on DNA Medicines: The company specializes in developing DNA medicines aimed at treating HPV-related diseases, cancer, and infectious diseases, with innovative technologies that enable the body to produce its own disease-fighting tools.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Company Progress and Financial Overview: Inovio Pharmaceuticals is focused on advancing its lead candidate INO-3107 for recurrent respiratory papillomatosis, with plans to submit a Biologics License Application (BLA) by mid-2025. The company reported a reduced net loss in Q4 2024 and emphasized financial discipline, maintaining a cash runway into early 2026.

Clinical Developments and Market Positioning: New clinical data indicates significant reductions in surgery needs post-treatment with INO-3107, positioning it as a potential preferred non-surgical option for RRP. Despite some risks related to manufacturing and competition, management remains optimistic about the product's market impact and ongoing advancements in DNA medicine technology.

Progress on INO-3107 BLA Submission: INOVIO is making significant strides towards submitting a biologics license application (BLA) for INO-3107, targeting recurrent respiratory papillomatosis (RRP), with plans to begin rolling submissions in mid-2025 and aiming for FDA acceptance by year-end 2025. Recent data shows promising patient outcomes, including a 50% complete response rate in the second year of treatment.

Advancements in DNA Medicine Technology: The company reported positive interim results from a Phase 1 trial of DNA-encoded monoclonal antibodies (DMAb) for COVID-19, demonstrating sustained antibody production without adverse immune responses, indicating potential for broader applications in treating various diseases.

Earnings Reports Today: Major companies such as Inovio Pharmaceuticals, Healthequity, and Tencent Music are set to report earnings today, with expected stock movements indicated by options prices.

Options Trading Insights: Investors can view the implied moves for each company based on their earnings release timing, with a note that options trading carries risks and requires thorough research.

Earnings Announcement: Inovio Pharmaceuticals is set to release its Q4 earnings results on March 18th, with an expected EPS of -$0.83 and revenue of $0.03M; historically, the company has beaten EPS estimates 50% of the time.

Recent Developments: The company has seen two upward revisions in EPS estimates over the last three months, while revenue estimates have experienced one downward revision; additionally, their respiratory DNA drug candidate shows promise in early trials.

Upcoming Earnings Reports: The week of March 17 to March 21 will feature earnings reports from various companies, including NIO, XPeng, FedEx, General Mills, and Micron Technology, providing insights into sectors like electric vehicles, technology, consumer goods, and shipping.

Market Expectations: Analysts have mixed expectations for these companies, with XPeng and NIO showing strong delivery growth but facing profitability concerns, while FedEx is under scrutiny after lowering its annual forecast, and Micron is highlighted as a key player in the AI semiconductor sector.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Promising Trial Results: INOVIO announced that its Phase 1 trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19 showed that all participants maintained effective antibody levels after 72 weeks, with no development of anti-drug antibodies.

Collaboration and Future Plans: The trial, conducted in partnership with The Wistar Institute, AstraZeneca, and the University of Pennsylvania, reported mild side effects and plans to present interim results at scientific conferences in 2025.

Long-lasting antibody production: A Phase 1 trial showed that DMAb levels remained stable for 72 weeks in all participants, with no immune rejection detected and mild side effects reported.

Potential breakthrough technology: The study demonstrates the effectiveness of DNA-encoded monoclonal antibodies, suggesting a promising platform for long-term therapeutic protein delivery across various diseases.

Promising Trial Results: Inovio's Phase 1 trial of DMAbs for COVID-19 showed that all participants maintained significant antibody levels after 72 weeks, with no adverse immune responses, indicating the potential durability and tolerability of this treatment approach.

Potential Breakthrough Technology: The study suggests that DNA-encoded monoclonal antibodies could address challenges in traditional antibody production, offering a transformative solution for treating infectious diseases, cancer, and metabolic disorders through long-term expression of therapeutic proteins.

Financial Results Announcement: INOVIO will release its fourth quarter and year-end 2024 financial results on March 18, 2025, followed by a live conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update.

Company Overview: INOVIO is a biotechnology company focused on developing DNA medicines for treating HPV-related diseases, cancers, and infectious diseases, utilizing technology that enables the body to produce its own disease-fighting tools.

Clinical Trial Results: INOVIO's Phase 1/2 trial of INO-3107 for recurrent respiratory papillomatosis (RRP) showed that 81% of patients required fewer surgeries post-treatment, indicating a significant clinical benefit and well-tolerated treatment with a strong immune response against HPV.

Future Plans: INOVIO plans to submit a biologics license application for INO-3107 in mid-2025, aiming for accelerated approval from the FDA, which could make it the first DNA medicine approved for any indication in the United States.

Presentation of Research Findings: INOVIO will present a poster at the American Association for Cancer Research conference detailing the loss of detectable HPV-6 in patients with Recurrent Respiratory Papillomatosis after treatment with INO-3107, highlighting its immunological activity.

About INOVIO: INOVIO is a biotechnology company focused on developing DNA medicines to combat HPV-related diseases, cancer, and infectious diseases, utilizing innovative technology to enhance disease-fighting capabilities.

INOVIO Presentation Announcement: INOVIO's President and CEO, Dr. Jacqueline Shea, along with Chief Medical Officer Dr. Michael Sumner, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, from 3:20 to 3:50 pm ET.

Company Focus: INOVIO is a biotechnology company dedicated to developing DNA medicines aimed at treating HPV-related diseases, cancer, and infectious diseases, utilizing innovative technology for disease-fighting solutions.

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.

Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and timely updates.

2025 Anticipated Milestones: INOVIO plans to submit a biologics license application for INO-3107 by mid-2025, aiming to become the first DNA medicine approved in the U.S. for recurrent respiratory papillomatosis (RRP), while also addressing manufacturing issues and initiating a confirmatory trial.

2024 Key Accomplishments: INOVIO reported significant clinical trial results showing improved response rates for RRP patients treated with INO-3107, alongside advancements in their pipeline including collaborations for Phase 3 trials and strengthening their financial position with over $60 million raised.

Stock Performance: Inovio Pharmaceuticals Inc's shares fell by 5.3% to $2.16 after a strong rally, likely due to profit-taking as investors focus on rising respiratory illness cases and vaccine developments.

Vaccine Development Focus: The company’s lead candidate, INO-4800, remains central to its strategy amid growing interest in alternative vaccine technologies, while it continues to advance its pipeline for other diseases like RSV and MERS.

Inovio Pharmaceuticals Stock Surge: Inovio Pharmaceuticals' shares rose by 17.9% to $2.27 due to heightened concerns over respiratory illnesses and increased interest in biotechnology stocks focused on infectious diseases, particularly amid reports of the first U.S. H5N1 death.

Vaccine Development Focus: The company is advancing its DNA-based vaccine technology, with a focus on its COVID-19 vaccine candidate INO-4800, as well as research on vaccines for other infectious diseases and cancers, leveraging its SynCon platform for new vaccine candidates.